Simultaneous quantification of 24 antiepileptic drugs from plasma or serum by LC-MS/MS for therapeutic drug monitoring.
24 drugs
3–5 working days
This comprehensive panel enables simultaneous monitoring of 24 antiepileptic drugs, supporting optimisation of seizure control while minimising adverse effects through individualised dosing.
Clinical indications include:
24 antiepileptic drugs including carbamazepine, oxcarbazepine, lamotrigine, valproic acid, phenytoin, phenobarbital, levetiracetam, topiramate, lacosamide, zonisamide, clobazam, clonazepam, and others.
All 24 drugs are quantified simultaneously by LC-MS/MS from a single plasma or serum sample, using stable isotope internal standards for each analyte. The method provides the specificity necessary to avoid cross-reactivity between structurally similar drugs and their metabolites.
From enquiry to results — a straightforward process.
This test is available to healthcare professionals, wellness brands, clinics, and research institutions worldwide. We currently serve partners in:
Whether you need testing services for your patients, white-label kits for your brand, or method transfer to your own laboratory — get in touch to discuss how we can work together.
Simultaneously quantifies 24 antiepileptic drugs from a single plasma or serum sample by LC-MS/MS. Covers all major AEDs including carbamazepine, valproate, lamotrigine, levetiracetam, and newer agents.
Antiepileptic drugs have narrow therapeutic windows — too little risks seizure breakthrough, too much risks toxicity. Individual metabolism varies widely, making blood level monitoring essential for dose optimisation.
Venous blood draw into plasma or serum tubes by a healthcare professional. Trough levels (just before the next dose) are typically recommended.
Results are typically delivered within 3 to 5 working days from the time your sample arrives at our laboratory. The analysis is performed by LC-MS/MS.
LC-MS/MS measures each drug individually without cross-reactivity from structurally similar drugs or metabolites. Immunoassays can over-estimate or under-estimate levels due to interference.
Masdiag's antiepileptic drug monitoring panel is available worldwide through our partner network. We currently serve healthcare professionals, wellness brands, and clinics in Europe, the United Kingdom, Asia, Australia, New Zealand, and the United States. Contact us to discuss testing services, white-label kits, or method transfer to your laboratory.
Whether you need testing services, method transfer, or white-label kit development — we'd love to hear from you.